Content about Lovenox

January 26, 2012

Federal court clears way for Watson, Amphastar to launch generic version of Lovenox

A federal court has stopped an injunction that would have prevented drug maker Watson Pharmaceuticals and partner company Amphastar Pharmaceuticals from marketing or selling a generic version of a blood-thinning drug.

November 14, 2011

Study: Pfizer, Bristol-Myers Squibb drug for internal blood clots not superior to enoxaparin

A drug under development by Pfizer and Bristol-Myers Squibb for preventing internal blood clots failed to show superiority over a treatment already on the market, the companies said Monday.

October 31, 2011

Court injunction stops Watson, Amphastar from marketing, selling Lovenox generic

Watson Pharmaceuticals and a partnering company are barred from launching a generic version of a blood-thinning drug under a federal court decision issued Friday.

September 20, 2011

Watson, Amphastar get go-ahead for generic Lovenox

The Food and Drug Administration has approved a generic version of a deep vein thrombosis treatment.

January 25, 2011

Teva receives FDA action letter for generic Lovenox

Teva on Tuesday confirmed its receipt of an action letter from the Food and Drug Administration for its generic blood-thinning drug.

December 20, 2010

FDA releases annual 'Generic Drug Roundup'

Drugs for bacterial infections and cancer, and one that could help shape regulations for biosimilars, are featured in the Food and Drug Administration’s annual "Generic Drug Roundup."

December 7, 2010

Momenta, Sandoz file patent suit against Teva over generic Lovenox

Drug makers Momenta Pharmaceuticals and Sandoz have filed a lawsuit against Teva Pharmaceutical Industries in the U.S. District Court for the District of Massachusetts, alleging infringement of two patents related to a generic blood-thinning drug.

November 14, 2010

Countdown to 2011: A big year for generics

The world of generic drugs has a big year ahead of it. Actually, it has...

September 26, 2010

Biosimilars, biogenerics, follow-on biologics—whatever the designation one prefers for knockoffs of biotech drugs—they will soon...